JP2023504744A5 - - Google Patents
Info
- Publication number
- JP2023504744A5 JP2023504744A5 JP2022534195A JP2022534195A JP2023504744A5 JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5 JP 2022534195 A JP2022534195 A JP 2022534195A JP 2022534195 A JP2022534195 A JP 2022534195A JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- rnai construct
- construct according
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026028952A JP2026122489A (ja) | 2019-12-09 | 2026-02-25 | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945777P | 2019-12-09 | 2019-12-09 | |
| US62/945,777 | 2019-12-09 | ||
| PCT/US2020/063844 WO2021119034A1 (en) | 2019-12-09 | 2020-12-08 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028952A Division JP2026122489A (ja) | 2019-12-09 | 2026-02-25 | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504744A JP2023504744A (ja) | 2023-02-06 |
| JP2023504744A5 true JP2023504744A5 (cg-RX-API-DMAC7.html) | 2023-12-13 |
| JP7827623B2 JP7827623B2 (ja) | 2026-03-10 |
Family
ID=74141837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534195A Active JP7827623B2 (ja) | 2019-12-09 | 2020-12-08 | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
| JP2026028952A Pending JP2026122489A (ja) | 2019-12-09 | 2026-02-25 | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028952A Pending JP2026122489A (ja) | 2019-12-09 | 2026-02-25 | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230078200A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073252A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7827623B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020399636A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163322A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007005A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119034A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250077604A (ko) * | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
| US20250283076A1 (en) * | 2021-09-14 | 2025-09-11 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041079A1 (zh) * | 2021-09-18 | 2023-03-23 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| KR20250043473A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| WO2024081954A2 (en) * | 2022-10-14 | 2024-04-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting c3 and uses thereof |
| TW202440921A (zh) * | 2022-12-05 | 2024-10-16 | 美商美國禮來大藥廠 | 經修飾之寡核苷酸 |
| CN121294438A (zh) * | 2022-12-19 | 2026-01-09 | 昂拓生物医药有限公司 | 高级rna靶向(arnatar) |
| WO2024138111A1 (en) * | 2022-12-23 | 2024-06-27 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| US20260209772A1 (en) * | 2022-12-23 | 2026-07-23 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| CN119384503A (zh) * | 2023-04-03 | 2025-01-28 | 翰森(上海)健康科技有限公司 | 靶向LPA基因的RNAi剂及其用途 |
| WO2024222686A1 (zh) * | 2023-04-24 | 2024-10-31 | 上海京新生物医药有限公司 | 用于抑制LPA表达的RNAi剂及其应用 |
| JP2026520116A (ja) * | 2023-05-11 | 2026-06-22 | 大睿生物 | MASP2遺伝子活性を制御するためのdsRNA分子 |
| CN118685405A (zh) * | 2023-06-20 | 2024-09-24 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| EP4741502A1 (en) | 2023-07-04 | 2026-05-13 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Dsrna molecule for inhibiting lp(a) gene expression and use thereof |
| TW202540420A (zh) * | 2023-11-15 | 2025-10-16 | 大陸商北京加科瑞康醫藥科技有限公司 | 用於抑制LPA的基因表現的siRNA,含其的組合物及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| CN117805370B (zh) * | 2023-12-29 | 2025-11-04 | 深圳市新产业生物医学工程股份有限公司 | 胶乳免疫比浊的检测试剂、试剂盒及检测方法 |
| WO2026006275A2 (en) | 2024-06-26 | 2026-01-02 | Amgen Inc. | Rnai constructs and methods for inhibiting expression of inhbe |
| WO2026026812A1 (zh) * | 2024-07-29 | 2026-02-05 | 成都先衍生物技术有限公司 | 一种具有双靶点基因抑制作用的核酸缀合物及其应用 |
| WO2026026811A1 (zh) * | 2024-07-29 | 2026-02-05 | 成都先衍生物技术有限公司 | 一种具有双靶点基因抑制作用的核酸缀合物及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| JP4335310B2 (ja) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用 |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CN119120476A (zh) * | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| SG11202105900UA (en) * | 2018-12-10 | 2021-07-29 | Amgen Inc | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
-
2020
- 2020-12-08 JP JP2022534195A patent/JP7827623B2/ja active Active
- 2020-12-08 US US17/783,232 patent/US20230078200A1/en active Pending
- 2020-12-08 WO PCT/US2020/063844 patent/WO2021119034A1/en not_active Ceased
- 2020-12-08 MX MX2022007005A patent/MX2022007005A/es unknown
- 2020-12-08 CA CA3163322A patent/CA3163322A1/en active Pending
- 2020-12-08 AU AU2020399636A patent/AU2020399636A1/en active Pending
- 2020-12-08 EP EP20838702.7A patent/EP4073252A1/en active Pending
-
2026
- 2026-02-25 JP JP2026028952A patent/JP2026122489A/ja active Pending